SCHEMBL60648

SCHEMBL60648

O=C(O)c1ccc(N2CCOCC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.67
GSK3B P49841 1/20 0.64
KDM4E B2RXH2 2/20 0.62
USP2 O75604 1/20 0.61
ALDH1A1 P00352 4/20 0.59
HPGD P15428 2/20 0.59
ALOX15 P16050 1/20 0.59
HSD17B10 Q99714 1/20 0.59
MAOB P27338 1/20 0.58
POLB P06746 1/20 0.56
MAPT P10636 5/20 0.56
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
TP53 P04637 2/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
LMNA P02545 1/20 0.55
PIK3CA P42336 2/20 0.54
PKM P14618 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6186324 0.98 KMO (0.65) KMOGSK3BKDM4EUSP2ALDH1A1
Hydrochloric Acid SCHEMBL6538516 0.96 KMO (0.63) KMOGSK3BKDM4EUSP2ALDH1A1
SCHEMBL6374645 0.94 KMO (0.61) KMOGSK3BKDM4EUSP2ALDH1A1
SCHEMBL17737077 0.91 KMO (0.57) KMOGSK3BKDM4EUSP2ALDH1A1
SCHEMBL19831259 0.90 MAPT (0.68) KMOGSK3BKDM4EUSP2ALDH1A1
SCHEMBL23610369 0.87 KDM4E (0.71) KDM4EUSP2ALDH1A1HPGDALOX15
SCHEMBL17737082 0.87 KDM4E (0.71) KDM4EUSP2ALDH1A1HPGDALOX15
SCHEMBL2742813 0.86 NPC1 (0.66) KMOGSK3BKDM4EUSP2ALDH1A1
SCHEMBL3824666 0.86 GSK3B (0.66) KMOGSK3BKDM4EALDH1A1HPGD
SCHEMBL1643417 0.85 KMO (0.68) KMOGSK3BKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-1188405-C New Morpholinobenzamide salts ASTRAZENECA AB (SE) 2005-02-09 CN claimed
US-20050010045-A1 Reacting morpholine compound with a substituted benzene compound TIAN WEI (SE) 2005-01-13 US claimed
US-6689882-B2 REACTING A MORPHOLINE WITH A SUBSTITUTED BENZENE, WHEREIN MORPHOLINE IS USED AS A REACTANT AND AS THE ONLY ONE SOLVENT ASTRAZENECA AB (SE) 2004-02-10 US claimed
US-20030171581-A1 Process for the synthesis of morpholinylbenzenes ASTRAZENECA AB (SE) 2003-09-11 US claimed
EP-1286977-A1 A NEW PROCESS FOR THE SYNTHESIS OF MORPHOLINYLBENZENES AstraZeneca AB (SE) 2003-03-05 EP claimed
EP-0623635-B1 Amine-functionalized polyester GEN ELECTRIC (US) 2003-02-19 EP claimed
CN-1337956-A New Morpholinobenzamide salts ASTRAZENECA AB (SE) 2002-02-27 CN claimed
WO-2001087865-A1 A NEW PROCESS FOR THE SYNTHESIS OF MORPHOLINYLBENZENES ASTRAZENECA AB (SE) 2001-11-22 WO claimed
EP-1149083-A1 MORPHOLINOBENZAMIDE SALTS AstraZeneca AB (SE) 2001-10-31 EP claimed
US-6291458-B1 Morpholinobenzamide salts ASTRAZENECA AB (SE) 2001-09-18 US claimed
WO-2000043378-A1 NEW MORPHOLINOBENZAMIDE SALTS ASTRAZENECA AB (SE) 2000-07-27 WO claimed
JP-4247074-A None JP disclosed
US-12522618-B2 Copper complexes for treatment of neurodegenerative disorders ALS THERAPY DEVELOPMENT INSTITUTE (US) 2026-01-13 US disclosed
EP-4301736-B1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2025-10-08 EP disclosed
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 WO disclosed
WO-1998048799-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO disclosed
WO-1997034883-A1 SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES ASTRA AKTIEBOLAG (SE) 1997-09-25 WO disclosed
JP-H04247074-A PRODUCTION OF 4-MORPHOLINOBENZOIC ACID DERIVATIVE YOSHITOMI PHARMACEUT IND LTD 1992-09-03 JP disclosed
US-4994569-A Cholecystokinin antagonists RHONE-POULENC SANTE (FR) 1991-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171581-A1 Process for the synthesis of morpholinylbenzenes CYP1B1, TBCB, MAP1B KMO 299/4885GSK3B 3101/4885KDM4E 2640/4885
US-20050010045-A1 Reacting morpholine compound with a substituted benzene compound CYP1B1, MYB, MYBBP1A KMO 237/4885GSK3B 4424/4885KDM4E 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.